Open-label Follow-up Study of the VIPES Study to Evaluate Long-term Efficacy and Safety of the Viaskin Peanut

Trial Profile

Open-label Follow-up Study of the VIPES Study to Evaluate Long-term Efficacy and Safety of the Viaskin Peanut

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Peanut allergy immunotherapy (Primary)
  • Indications Peanut hypersensitivity
  • Focus Therapeutic Use
  • Acronyms OLFUS-VIPES
  • Sponsors DBV Technologies
  • Most Recent Events

    • 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 11 Nov 2016 According to a DBV Technologies media release, results of single-center assessment were presented at the American College of Allergy, Asthma, and Immunology (ACAAI) 2016 meeting.
    • 11 Nov 2016 According to a DBV Technologies media release, additional biomarker data based on VIPES and OLFUS-VIPES trials were presented at the American College of Allergy, Asthma, and Immunology (ACAAI) 2016 meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top